Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics:

• Mechanisms of endocrine resistance; incidence of ESR1 mutations in breast cancer (0:00)
• Testing methods for ESR1 mutations in patients with breast cancer; therapeutic options for patients with ESR1-mutant breast cancer (3:59)
• General overview of proteolysis-targeting chimeras (PROTACs); comparison of PROTAC estrogen receptor (ER) degraders and selective ER degraders (7:39)
• Early-phase data with vepdegestrant monotherapy or in combination with CDK4/6 inhibitors in ER-positive, HER2-negative metastatic breast cancer (mBC) (11:54)
• Phase III VERITAC-2 trial of vepdegestrant versus fulvestrant in ER-positive, HER2-negative mBC previously treated with endocrine therapy and a CDK4/6 inhibitor (17:48)
• Ongoing clinical trials evaluating vepdegestrant in novel combinations or treatment settings; other clinical applications of PROTACs (26:08)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson and Dr Manali Kamdar, including the following topics:

• Introduction: About This Program (0:00)
• Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (3:10)
• Potential Treatment Benefits of CAR T-Cell Therapy (10:35)
• CRS (Cytokine Release Syndrome) and ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) (34:32)
• Finding Information About CAR T; Clinical Trials (42:17)
• Financial Issues; Risk of Infection (48:11)
• Coping with Anxiety; Healing and Moving On (55:17)

Educational and presenter information

Featuring slide presentations and related discussion from Prof Francois-Clement Bidard, Dr Hope S Rugo, Dr Rebecca Shatsky and Dr Seth Wander, including the following topics:

• Optimal approach to biomarker testing for patients with ER-positive metastatic breast cancer (mBC) (0:00)
• Case: A woman in her early 70s with recurrent ER-positive, HER2-negative mBC receives elacestrant (15:15)
• Case: A woman in her early 60s with ER-positive, HER2-low, PIK3CA-mutated mBC receives inavolisib-based therapy and experiences no disease progression for 24 months (18:02)
• Role of oral selective estrogen receptor degrader (SERD) monotherapy in the treatment of progressive ER-positive, HER2-negative mBC (26:26)
• Case: A woman in her mid 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (44:12)
• Case: A woman in her early 50s with recurrent HR-positive, HER2-negative, PIK3CA-mutant mBC receives capivasertib and fulvestrant (45:33)
• Potential novel applications of oral SERDs in the management of ER-positive, HER2-negative breast cancer (51:25)
• Case: A woman in her mid 50s with recurrent ER-positive, HER2-negative, PIK3CA-mutated mBC experiences disease progression 18 months after starting first-line letrozole and ribociclib (1:03:46)
• Case: A woman in her mid 50s with ER-positive, HER2-negative breast cancer undergoes serial ctDNA monitoring during first-line therapy (1:06:54)
• Tolerability and other practical considerations with oral SERDs (1:14:30)
• Case: A woman in her early 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (1:33:26)
• Case: A woman in her early 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (1:37:38)

CME information and select publications

Featuring perspectives from Dr Matthew Lunning and Dr Sonali M Smith, including the following topics:

• Which Driver and Which Race: CAR-T and Bispecific Antibodies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Dr Lunning (0:00)
• Available and Emerging Novel Therapies for Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Dr Smith (32:37)

CE information and select publications

Featuring perspectives from Dr Emmanuel S Antonarakis and Dr Matthew R Smith, including the following topics:

• Current and Future Role of Immune Checkpoint Inhibitors in the Management of Colorectal Cancer — Dr Lieu (0:00)
• Other Biomarker-Based Strategies for Patients with Colorectal Cancer — Dr Strickler (36:39)

CE information and select publications

Featuring perspectives from Dr Emmanuel S Antonarakis and Dr Matthew R Smith, including the following topics:

• Introduction (0:00)
• Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Smith (0:55)
• Available and Emerging Therapeutic Approaches for Metastatic Castration-Resistant Prostate Cancer — Dr Antonarakis (26:37)

CE information and select publications

Featuring perspectives from Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda, including the following topics:

• Introduction (0:00)
• Localized Hormone Receptor (HR)-Positive Breast Cancer; Initial Therapy for Metastatic Disease — Dr Goetz (4:48)
• Relapsed/Refractory HR-Positive Metastatic Breast Cancer — Dr Nanda (29:45)
• Management of HER2-Positive Breast Cancer — Dr Burstein (1:04:43)
• Antibody-Drug Conjugate Treatment Approaches for Triple-Negative Breast Cancer — Dr McArthur (1:29:53)

CE information and select publications

Featuring an interview with Dr Aaron Lisberg, including the following topics:

• Prevention and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (Dato-DXd) (0:00)
  • Rugo H et al. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Support Care Cancer 2025;33(9):756. Abstract
  • Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;[Online ahead of print]. Abstract
  • Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 2025;30(3). Abstract
• Novel Strategies Combining Dato-DXd with Osimertinib (10:44)
  • Lu S et al. TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC). ASCO 2025;Abstract TPS8647.
  • Nadal E et al. TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib. ELCC 2025;Abstract 124TiP.
• Intracranial Activity Observed with TROP2-Targeting Antibody-Drug Conjugates (15:14)
  • Felip E et al. Brain metastases and actionable genetic alterations with sacituzumab govitecan versus docetaxel in metastatic non-small cell lung cancer: Subgroups of the phase III EVOKE-01 trial. ELCC 2025;Abstract 13P.
  • Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.
  • Pons-Tostivint E et al. Intracranial efficacy of datopotamab deruxtecan (Dato- DXd) in patients with advanced/metastatic NSCLC in TROPION-Lung01. WCLC 2025;Abstract OA10.01.

CME information and select publications